Stocks Health care BLCO
NYSE · Health careBausch & Lomb Corp (BLCO)
Bausch & Lomb Corp brought in $5.4B of revenue over the twelve months to September 30, 2026, up 8.9% from a year earlier. It posted a net loss of $111M. In fiscal 2025 capital spending exceeded operating cash flow by $66M. At September 30, 2026 it held $513M in cash against $5B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 28, 2026.
Key facts about Bausch & Lomb Corp
- Net worth
- Bausch & Lomb Corp has a market value (market cap) of $7.5B at the latest share price, and shareholders' equity of $6.4B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $5.1B (+6.5% year on year), with a net loss of $360M. Over the 12 months to September 30, 2026: revenue $5.4B, net loss $111M.
- Cash flow
- In fiscal 2025 operations brought in $283M of cash; after $349M of capital spending, free cash flow was -$66M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 28, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Bausch & Lomb Corp's next report is expected around February 17, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Bausch & Lomb Corp does
Bausch & Lomb Corp is registered with the SEC under industry code SIC 3851 (Ophthalmic Goods). Its shares trade on NYSE under the ticker BLCO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $5.1B | -$360M | -$1.02 | -$66M |
| 2024 | $4.8B | -$317M | -$0.90 | -$59M |
| 2023 | $4.1B | -$260M | -$0.74 | -$198M |
| 2022 | $3.8B | $6M | $0.02 | $170M |
| 2022 | $3.8B | $182M | $0.52 | $680M |
| 2020 | $3.4B | -$18M | -$0.05 | $269M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where BLCO ranks in Health care
Latest SEC filings
What Bausch & Lomb Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 28, 2026
- October 28, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 7.3% to $1.4B versus the same quarter last year; diluted EPS $0.09 versus -$0.08.
- October 28, 2026
- October 13, 2026
- August 12, 2026
- August 6, 2026
- July 29, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 9.1% to $1.4B versus the same quarter last year; diluted EPS -$0.04 versus -$0.18.
- July 29, 2026
- June 1, 2026
- May 20, 2026
Insider trades
What the people running Bausch & Lomb Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $2.3M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 29, 2026 | Alfonso EduardoDirector | Received as pay | 1,125 | $23K |
| October 29, 2026 | Paulson JohnDirector | Received as pay | 1,125 | $23K |
| October 29, 2026 | Robertson Russel CDirector | Received as pay | 1,256 | $25.6K |
| October 29, 2026 | Munsch FrederickSVP, Controller and CAO | Exercised options | 24,103 | $432.9K |
| October 29, 2026 | Munsch FrederickSVP, Controller and CAO | Exercised options | 87,912 | $1.6M |
| October 29, 2026 | Munsch FrederickSVP, Controller and CAO | Sold | 112,015 | $2.3M |
| August 12, 2026 | Chersi Robert JDirector | Received as pay | 11,776 | - |
| August 12, 2026 | Paul Laurence EDirector | Received as pay | 11,776 | - |
Who owns BLCO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
19 insiders reported holding 3,015,520 shares in total, about $63.2M at the last price.
| Holder | Shares |
|---|---|
| Saunders Brent LChairman of the Board and CEO, Director | 1,256,037 |
| Eldessouky SamEVP and CFO | 393,527 |
| Bailey A Robert DEVP & Chief Legal Officer | 264,241 |
| Hashad YehiaEVP of R&D and CMO | 187,350 |
| Bonnefoy LucPresident, Surgical | 103,801 |
| Stewart Andrew J.President, GPIC | 103,211 |
| Robertson Russel CDirector | 95,516 |
| Paulson JohnDirector | 90,948 |
| Bernier Nathalie D.Director | 85,505 |
| Ross Thomas W. Sr.Director | 85,233 |
Questions about BLCO
What does Bausch & Lomb Corp do?
Bausch & Lomb Corp is a company in the Health care sector, listed on NYSE as BLCO. Its shares trade on NYSE under the ticker BLCO.
What is Bausch & Lomb Corp's net worth?
Bausch & Lomb Corp has a market value (market cap) of $7.5B at the latest share price, and shareholders' equity of $6.4B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Bausch & Lomb Corp profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $111M on revenue of $5.4B.
How much revenue does Bausch & Lomb Corp make?
Over the twelve months to September 30, 2026 Bausch & Lomb Corp reported revenue of $5.4B. That is 8.9% more than a year earlier.
When did Bausch & Lomb Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 28, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the planned insider sale from November 3, 2026.
When is Bausch & Lomb Corp's next earnings report?
Bausch & Lomb Corp's next report is expected around February 17, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare BLCO with
Follow BLCO
Get an email when Bausch & Lomb Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Bausch & Lomb Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.